Immunosuppressive agents: recent developments in molecular action and clinical application.
Gerber
D A
DA
Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, PA 15213, USA.
Bonham
C A
CA
Thomson
A W
AW
D016572:Cyclosporine / Q000494:pharmacology / Q000627:therapeutic use; D006146:Guanidines / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D007555:Isoxazoles / Q000494:pharmacology / Q000627:therapeutic use; D000077339:Leflunomide; D008954:Models, Biological; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D011090:Polyenes / Q000494:pharmacology / Q000627:therapeutic use; D012263:Ribonucleosides / Q000494:pharmacology / Q000627:therapeutic use; D020123:Sirolimus; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D016559:Tacrolimus / Q000494:pharmacology / Q000627:therapeutic use; D014181:Transplantation Immunology
D006146:Guanidines; D007166:Immunosuppressive Agents; D007555:Isoxazoles; D011090:Polyenes; D012263:Ribonucleosides; C010052:mizoribine; D016572:Cyclosporine; D000077339:Leflunomide; D009173:Mycophenolic Acid; C037258:gusperimus; D020123:Sirolimus; D016559:Tacrolimus